CytomX Therapeutics, Inc. (CTMX)
NASDAQ$0.6496
Market Cap
$50.84M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
541 of 924
Rank in Industry
314 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
CTMX Insider Trading Activity
CTMX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $134,664 | 10 | 100 |
Related Transactions
| Ogden Christopher | SVP, Finance and Accounting | 0 | $0 | 2 | $8,635 | $-8,635 |
| ROWLAND LLOYD A | General Counsel | 0 | $0 | 2 | $16,125 | $-16,125 |
| Landau Jeffrey B | Chief Business Officer | 0 | $0 | 2 | $18,824 | $-18,824 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | 0 | $0 | 2 | $31,823 | $-31,823 |
| McCarthy Sean A. | CEO | 0 | $0 | 2 | $59,257 | $-59,257 |
About CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and …
Insider Activity of CytomX Therapeutics, Inc.
Over the last 12 months, insiders at CytomX Therapeutics, Inc. have bought $0 and sold $134,664 worth of CytomX Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at CytomX Therapeutics, Inc. have bought $7,750 and sold $459,277 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $7,750 was made by Jones Elaine V (director) on 2023‑03‑29.
List of Insider Buy and Sell Transactions, CytomX Therapeutics, Inc.
| 2024-08-20 | Sale | McCarthy Sean A. | CEO | 13,898 0.0176% | $1.23 | $17,082 | -15.32% | |
| 2024-08-20 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 4,181 0.0053% | $1.23 | $5,139 | -15.32% | |
| 2024-08-20 | Sale | ROWLAND LLOYD A | General Counsel | 4,181 0.0053% | $1.23 | $5,139 | -15.32% | |
| 2024-08-20 | Sale | Landau Jeffrey B | Chief Business Officer | 4,181 0.0053% | $1.23 | $5,139 | -15.32% | |
| 2024-08-20 | Sale | Ogden Christopher | Chief Financial Officer | 1,984 0.0025% | $1.23 | $2,439 | -15.32% | |
| 2024-03-19 | Sale | McCarthy Sean A. | CEO | 20,223 0.0286% | $2.09 | $42,175 | -45.41% | |
| 2024-03-19 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 12,795 0.0181% | $2.09 | $26,684 | -45.41% | |
| 2024-03-19 | Sale | ROWLAND LLOYD A | General Counsel | 5,268 0.0074% | $2.09 | $10,986 | -45.41% | |
| 2024-03-19 | Sale | Landau Jeffrey B | Chief Business Officer | 6,562 0.0093% | $2.09 | $13,685 | -45.41% | |
| 2024-03-19 | Sale | Ogden Christopher | SVP, Finance and Accounting | 2,971 0.0042% | $2.09 | $6,196 | -45.41% | |
| 2023-12-20 | Sale | McCarthy Sean A. | CEO | 13,551 0.0208% | $1.38 | $18,710 | +5.60% | |
| 2023-12-20 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 4,077 0.0063% | $1.38 | $5,628 | +5.60% | |
| 2023-12-20 | Sale | ROWLAND LLOYD A | General Counsel | 4,077 0.0063% | $1.38 | $5,629 | +5.60% | |
| 2023-12-20 | Sale | Landau Jeffrey B | Chief Business Officer | 4,077 0.0063% | $1.38 | $5,628 | +5.60% | |
| 2023-12-20 | Sale | Ogden Christopher | SVP, Finance and Accounting | 1,990 0.0031% | $1.38 | $2,747 | +5.60% | |
| 2023-09-22 | Sale | McCarthy Sean A. | CEO | 14,601 0.0222% | $1.30 | $18,987 | +12.50% | |
| 2023-09-22 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 4,119 0.0063% | $1.30 | $5,356 | +12.50% | |
| 2023-09-22 | Sale | ROWLAND LLOYD A | General Counsel | 5,486 0.0083% | $1.30 | $7,135 | +12.50% | |
| 2023-09-22 | Sale | Landau Jeffrey B | Chief Business Officer | 4,119 0.0063% | $1.30 | $5,356 | +12.50% | |
| 2023-03-29 | Jones Elaine V | director | 5,000 0.0076% | $1.55 | $7,750 | +0.98% |
Total: 162
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| ROWLAND LLOYD A | General Counsel | 130797 0.1671% | $84,965.73 | 1 | 6 | <0.0001% |
| Flynn James E | 10 percent owner | 671024 0.8574% | $435,897.19 | 1 | 0 | <0.0001% |
| GLUCK FREDERICK W | director | 271643 0.3471% | $176,459.29 | 1 | 8 | <0.0001% |
| Kavanaugh William Michael | CSO, Head Res.&Non-Clin. Dev. | 13917 0.0178% | $9,040.48 | 1 | 1 | <0.0001% |
| Jones Elaine V | director | 5142 0.0066% | $3,340.24 | 1 | 0 | +0.98% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$15,956,086 | 53 | 5.33% | $46.1M | |
$81,638,324 | 48 | 7.58% | $49.31M | |
$18,274,594 | 22 | -26.07% | $49.68M | |
$160,539,875 | 21 | -6.57% | $46.76M | |
$26,736,140 | 20 | -18.64% | $54.85M |
CTMX Institutional Investors: Active Positions
| Increased Positions | 37 | +45.68% | 7M | +14.28% |
| Decreased Positions | 34 | -41.98% | 12M | -23.54% |
| New Positions | 13 | New | 3M | New |
| Sold Out Positions | 13 | Sold Out | 9M | Sold Out |
| Total Postitions | 84 | +3.7% | 47M | -9.25% |
CTMX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Tang Capital Management Llc | $4,950.00 | 9.37% | 7.31M | -500,000 | -6.4% | 2024-12-31 |
| Bvf Inc/Il | $3,540.00 | 6.7% | 5.23M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $3,495.00 | 6.62% | 5.16M | 0 | 0% | 2024-12-31 |
| Prosight Management, Lp | $2,644.00 | 5.01% | 3.9M | +882,891 | +29.21% | 2024-12-31 |
| Millennium Management Llc | $2,181.00 | 4.13% | 3.22M | +660,756 | +25.81% | 2024-12-31 |
| Acadian Asset Management Llc | $2,124.00 | 4.02% | 3.14M | +36,052 | +1.16% | 2024-12-31 |
| Point72 Asset Management, L.P. | $1,794.00 | 3.4% | 2.65M | +3M | New | 2024-12-31 |
| Jacobs Levy Equity Management, Inc | $1,047.00 | 1.98% | 1.55M | +23,139 | +1.52% | 2024-12-31 |
| Schonfeld Strategic Advisors Llc | $935.00 | 1.77% | 1.38M | +169,000 | +13.95% | 2024-12-31 |
| Renaissance Technologies Llc | $912.00 | 1.73% | 1.35M | +331,800 | +32.69% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.